BridgeBio Oncology Therapeutics Inc. (BBOT) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 186K | 0 | 0 | 0 | 0 | 0 | 156K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -186K | 0 | 0 | 0 | 0 | 0 | -156K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | 100% | - | - | - | - | - | - | - |
| Operating Expenses | 45.99M | 43.41M | 49.18M | 30.09M | 23.14M | 21.88M | 19.66M | 23.87M | 15.45M | 41.69K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.38M | 5.33M | 14.13M | 2.65M | 2.5M | 2.34M | 1.77M | 1.36M | 2.28M | 0 |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 39.8M | 38.07M | 35.05M | 27.44M | 20.64M | 19.54M | 17.89M | 22.51M | 13.17M | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -186K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41.69K |
| Operating Income | -46.18M | -43.41M | -49.18M | -30.09M | -23.14M | -21.88M | -19.66M | -23.87M | -15.45M | -41.69K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -99.59% | -98.4% | -150.11% | -26.07% | -49.76% | -52377.69% | - | - | - | - |
| EBITDA | -45.99M | -43.21M | -49M | -29.91M | -23.08M | -21.83M | -19.61M | -23.82M | -15.4M | -41.69K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -99.25% | -97.98% | -149.85% | -25.58% | -49.92% | -52252.97% | - | - | - | - |
| D&A (Non-Cash Add-back) | 186K | 194K | 181K | 181K | 54K | 52K | 52K | 52K | 52K | 0 |
| EBIT | -46.18M | -43.41M | -49.18M | -30.09M | -23.14M | -21.88M | -19.66M | -23.87M | -15.45M | -41.69K |
| Net Interest Income | 3.94M | 4.42M | 3.44M | 2.08M | 1.81M | 2.25M | 2.56M | 2.44M | 1.21M | 0 |
| Interest Income | 3.94M | 4.42M | 3.44M | 2.08M | 1.81M | 2.25M | 2.56M | 2.44M | 1.21M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.07M | 4.61M | 4.42M | 1.66M | 1.08M | 2.17M | 2.34M | 2.36M | 1.17M | 0 |
| Pretax Income | -42.11M | -38.8M | -44.76M | -28.43M | -22.05M | -19.69M | -17.32M | -21.82M | -15.44M | -41.69K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -42.11M | -38.8M | -44.76M | -28.43M | -22.05M | -19.69M | -17.32M | -21.82M | -15.44M | -41.69K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -90.91% | -97.07% | -158.37% | -30.3% | -42.82% | -47120.09% | - | - | - | - |
| Net Income (Continuing) | -42.11M | -38.8M | -44.76M | -28.43M | -22.05M | 1.95M | -17.32M | 2.21M | 1.1M | -41.69K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.35 | -1.25 | -1.90 | -1.21 | -0.94 | 0.12 | -0.74 | 0.09 | 0.05 | -0.00 |
| EPS Growth % | -43.62% | -1141.67% | -156.76% | -1385.87% | -1980% | - | - | - | - | - |
| EPS (Basic) | -1.35 | -1.25 | -1.90 | -1.21 | -0.94 | 0.12 | -0.74 | 0.09 | 0.05 | -0.00 |
| Diluted Shares Outstanding | 31.14M | 31.14M | 23.51M | 23.51M | 23.51M | 16.64M | 23.51M | 23.51M | 22M | 20.48M |
| Basic Shares Outstanding | 31.14M | 31.14M | 23.51M | 23.51M | 23.51M | 16.64M | 23.51M | 23.51M | 22M | 20.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |